Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.
3-Benzimidazol-2-yl-1H-indazole analogs were developed as inhibitors of receptor tyrosine kinases (RTK). The synthesis and SAR of this series is reported.
McBride
Christopher M
CM
Small Molecule Drug Discovery, Biopharma Division, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA.
Renhowe
Paul A
PA
Heise
Carla
C
Jansen
Johanna M
JM
Lapointe
Gena
G
Ma
Sylvia
S
Piñeda
Ramon
R
Vora
Jayesh
J
Wiesmann
Marion
M
Shafer
Cynthia M
CM
D000818:Animals; D001562:Benzimidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D018360:Crystallography, X-Ray; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D007191:Indazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D008958:Models, Molecular; D015394:Molecular Structure; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D001562:Benzimidazoles; D007191:Indazoles; D020794:Receptor Protein-Tyrosine Kinases